TENX trades 80.6% below Wall Street's consensus target of $21.67.
Last 12 months price action with 12-month analyst target path
The base valuation assumes TENX achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 22, 2026, Tenax Therapeutics, Inc. (TENX) has a Wall Street consensus price target of $21.67, based on estimates from 4 covering analysts. With the stock currently trading at $12.00, this represents a potential upside of +80.6%. The company has a market capitalization of $543M.
Analyst price targets range from a low of $20.00 to a high of $25.00, representing a 23% spread in expectations. The median target of $20.00 differs from the mean, suggesting potential outlier estimates. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, TENX trades at a trailing P/E of -9.0x. Analysts expect EPS to grow -52.1% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
ATHAAthira Pharma, Inc. | $17M | $4.34 | — | — | — | — | — |
NKTRNektar Therapeutics | $1.2B | $60.98 | $149.60 | +145.3% | Buy | — | 33 |
ACADACADIA Pharmaceuticals Inc. | $3.7B | $21.62 | $33.67 | +55.7% | Buy | 55.6x | 37 |
PRTAProthena Corporation plc | $468M | $8.93 | $19.00 | +112.8% | Buy | 191.2x | 28 |
IMVTImmunovant, Inc. | $7.3B | $35.34 | $45.00 | +27.3% | Buy | — | 23 |
MDGLMadrigal Pharmaceuticals, Inc. | $11.7B | $505.75 | $710.22 | +40.4% | Buy | — | 23 |
ESPREsperion Therapeutics, Inc. | $655M | $3.15 | $3.19 | +1.3% | Hold | — | 25 |
RCKTRocket Pharmaceuticals, Inc. | $366M | $3.35 | $5.00 | +49.3% | Buy | — | 19 |
ARDXArdelyx, Inc. | $1.5B | $6.05 | $17.00 | +181.0% | Buy | — | 16 |
XNCRXencor, Inc. | $927M | $12.64 | $35.30 | +179.3% | Buy | — | 27 |
Quick answers to the most common questions about buying TENX stock.
The consensus Wall Street price target for TENX is $21.67, representing 80.6% upside from the current price of $12. With 4 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
TENX has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $21.67 implies 80.6% upside from current levels.
TENX's current price is $12 with a consensus target of $21.67 (80.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $25 for TENX, while the most conservative target is $20. The consensus of $21.67 represents the median expectation. These targets typically reflect 12-month expectations.
TENX is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month TENX stock forecast based on 4 Wall Street analysts shows a consensus price target of $21.67, with estimates ranging from $20 (bear case) to $25 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on TENX, with a "Buy" consensus rating and $21.67 price target (80.6% upside). 4 of 4 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
TENX analyst price targets range from $20 to $25, a 23% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $21.67 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.